

Article

# A Short and Efficient Total Synthesis of Ficuseptamines A and B

Hani Mutlak A. Hassan

King Fahd Medical Research Center, King Abdulaziz University, P.O. Box 80216, Jeddah 21589, Saudi Arabia; hmahassan@kau.edu.sa

Received: 11 July 2018; Accepted: 23 July 2018; Published: 26 July 2018




**Abstract:** A rapid and efficient total synthesis of ficuseptamines A and B by a cross metathesis strategy is described.

**Keywords:** ficuseptamines A and B; cross metathesis; total synthesis

## 1. Introduction

Ficuseptamines A, B, and C (**1a–c**) were isolated from the leaves of *Ficus septica* and reported by Shin-ya and co-workers in 2009 (Figure 1) [1]. Ficuseptamines A and B possess an aminocaprophenone structure, while ficuseptamine C contains a pyrrolidine moiety in its structure. After their isolation, these alkaloids were evaluated for cytotoxicity against HeLa (human cervical carcinoma) and ACC-MESO-1 (malignant pleural mesothelioma) cancer cell lines. Ficuseptamine A displayed  $IC_{50}$  values of 57  $\mu$ M and 160  $\mu$ M against HeLa and ACC-MESO-1 cells lines, respectively. Ficuseptamine B showed better cytotoxicity against the same cell lines ( $IC_{50}$ : 23  $\mu$ M for HeLa; 72  $\mu$ M for ACC-MESO-1), while ficuseptamine C showed no activity against either cell line. The aryl ketone motif, which is present in ficuseptamines A and B, is frequently found in natural products [2,3] and biologically active molecules [4]. We were interested in devising a novel strategy targeting ficuseptamines A and B for their first total synthesis. We thought that designing an efficient and facile strategy for their rapid total synthesis would offer the possibility of synthesizing ficuseptamine A and B analogues for biological evaluation, given the commercial availability of a wide variety of functionalized terminal olefins, which could be utilized in library design and synthesis. In addition, the incorporation of fluorine atom(s) into ficuseptamines A and B to synthesize fluorinated analogues could also significantly improve their biological activity [5,6].



**Figure 1.** Structures of ficuseptamine A, B, and C (**1a–c**).

Olefin metathesis is one of the most useful carbon–carbon bond-forming reactions, and it has found tremendous use in organic chemistry for the construction of a myriad of organic molecules [7–10].

This highly powerful transformation has also been elegantly utilized in the total synthesis of numerous natural products [11,12]. Olefin metathesis catalysts that promote this transformation are displayed in Figure 2. Cross metathesis (CM) is one of the most popular transformations for connecting two independent olefins together to form a more complex olefinic product, which could require several steps to synthesize if a different methodology was employed. Although ring-closing metathesis (RCM) has found extensive use in the total synthesis of numerous natural products, CM has become increasingly popular in the field of total synthesis [13–15], particularly after the discovery of Z-selective olefin metathesis catalysts [16]. As part of our interest in the power of olefin metathesis to facilitate useful transformations [17], we report herein a highly efficient methodology for the total synthesis of ficuseptamines A and B, utilizing a cross metathesis approach.





Figure 2. Ruthenium-based olefin metathesis catalysts.

## 2. Results and Discussion


A retrosynthetic analysis of ficuseptamines A and B is depicted in Scheme 1. We commenced the synthetic work by first targeting ficuseptamine A for total synthesis. Aryl ketone **9a** was prepared in two sequential steps from commercially available alcohol **11** via halogenation and dehydrohalogenation reactions (Scheme 2).



Scheme 1. Retrosynthetic analysis of ficuseptamines A and B.

Thus, primary alcohol **11** was transformed into its bromo counterpart (i.e., **12**), under the influence of hydrobromic acid to furnish **12** in high yield (93%). Subsequent treatment of the brominated


product **12** with DBU (1,8-diazabicyclo[5.4.0]undec-7-ene) delivered CM precursor **9a** in 69% yield through dehydrobromination.



**Scheme 2.** Bromination of **11** followed by dehydrobromination with DBU to give CM precursor **9a**.

Next, we explored the key CM reaction between **9a** and *N,N*-dimethyl-4-pentene-1-amine **10** to afford the  $\alpha,\beta$ -unsaturated CM product **8a**. We initially performed the CM reaction using Grubbs I catalyst **4** (5 mol %) with  $\text{CH}_2\text{Cl}_2$  as a solvent to afford CM product **8a** in 22% yield (entry 1, Table 1). Increasing the Grubbs I catalyst **4** loading (10 mol %) provided **8a** in a disappointing 15% yield (entry 2, Table 1). We then turned our attention to Grubbs II catalyst **5**, which gave the CM product **8a** in modest 37 and 41% yields using 5 mol % and 10 mol % catalyst loading in  $\text{CH}_2\text{Cl}_2$ , respectively (entries 3 and 4, Table 1). Switching the solvent from  $\text{CH}_2\text{Cl}_2$  to toluene and performing the reaction with Grubbs II catalyst **5** (10 mol %) at 80 °C improved the yield to 47% (entry 5, Table 1).

**Table 1.** Optimization of the CM reaction.




E	Substrate <b>9a</b> (equiv.)	Substrate <b>10</b> (equiv.)	Catalyst (Loading)	Solvent	T (°C)	Yield % <sup>a</sup>
1	2	1	G I <b>4</b> (5 mol %)	$\text{CH}_2\text{Cl}_2$	40	22
2	2	1	G I <b>4</b> (10 mol %)	$\text{CH}_2\text{Cl}_2$	40	15
3	2	1	G II <b>5</b> (5 mol %)	$\text{CH}_2\text{Cl}_2$	40	37
4	2	1	G II <b>5</b> (10 mol %)	$\text{CH}_2\text{Cl}_2$	40	41
5	2	1	G II <b>5</b> (10 mol %)	Toluene	80	47
6	2	1	H-G II <b>7</b> (5 mol %)	$\text{CH}_2\text{Cl}_2$	40	68
7	2	1	H-G II <b>7</b> (10 mol %)	$\text{CH}_2\text{Cl}_2$	40	76
8	2	1	H-G II <b>7</b> (10 mol %)	Toluene	80	52
9	1	2	H-G II <b>7</b> (10 mol %)	$\text{CH}_2\text{Cl}_2$	40	42

<sup>a</sup> All reactions were performed using **9a** (2 mmol), **10** (1 mmol), solvent, and temperature for 10 h, except entry 9, in which the reaction was carried out using **9a** (1 mmol) and **10** (2 mmol). E = entry.

A report by Grubbs and co-workers described how the presence of the phosphine ligand ( $\text{PCy}_3$ ) in olefin metathesis catalysts can attack the carbene through its dissociation from the metal complex via decomposition [18]. This fact turned our attention to Hoveyda-Grubbs II **7**, which lacks the  $\text{PCy}_3$  ligand. Pleasingly, the use of Hoveyda-Grubbs II **7** (5 mol %) increased the yield significantly, to afford


**8a** in a 68% yield using  $\text{CH}_2\text{Cl}_2$  as the solvent (entry 6, Table 1). Treating **9a** and **10** with an increased Hoveyda-Grubbs II **7** loading (10 mol %) in  $\text{CH}_2\text{Cl}_2$  provided **8a** in an excellent 76% yield (entry 7, Table 1). In contrast, increasing the temperature to 80 °C and changing the solvent from  $\text{CH}_2\text{Cl}_2$  to toluene diminished the yield to 52% (compare entry 7 vs. 8, Table 1). The double bond geometry of the CM product **8a** was identified as the (*E*)-configured isomer, indicating that CM proceeded selectively to give the thermodynamically stable (*E*)-isomer exclusively. A change in molar ratio of the coupling partners **9a** and **10**, and performing the reaction using 10 mol % of Hoveyda-Grubbs II **7** in  $\text{CH}_2\text{Cl}_2$ , resulted in a reduction of the yield to 42%, with formation of the homodimer of **10** as a competing side-product (entry 9, Table 1). Grubbs and co-workers categorized olefin metathesis substrates as Type I, Type II, Type III, or Type IV [19]. According to Grubbs' selectivity model, terminal olefin **10** is a Type I olefin substrate, which usually undergoes fast homodimerization, while olefin **9a** is a Type II olefin, which undergoes slow homodimerization. Thus, such a change in the ratio of the coupling partners **9a** and **10** has promoted homodimerization of **10** to occur.

With synthesis of compound **8a** accomplished through CM, saturation of the newly formed double bond ( $\text{Pd/C}$ ,  $\text{H}_2$ ,  $\text{CH}_3\text{OH}$ , r.t., 16 h) proceeded smoothly to provide ficuseptamine A in 62% isolated yield. We then envisioned performing one-pot CM/hydrogenation reactions for the synthesis of ficuseptamine A without isolation of the unsaturated CM product **8a**. In fact, a literature screen revealed that such a CM/hydrogenation maneuver had been reported by Cossy and co-workers in their total synthesis of (-)-centrolobine [20]. One-pot sequential reactions are increasingly being utilized in organic synthesis to accelerate the synthesis of target molecules [21]. Motivated by Cossy's work, we subjected aryl ketone **9a** and terminal olefin **10** to our optimized CM conditions, followed by hydrogenation in a one-pot fashion, to afford ficuseptamine A in 65% yield directly from the starting materials **9a** and **10** (Scheme 3). This one-pot CM/hydrogenation sequence proved to be fruitful, thus improving the efficiency of the synthesis of ficuseptamine A.



**Scheme 3.** Improving ficuseptamine A (**1a**) synthesis by a one-pot CM/hydrogenation sequence.

With ficuseptamine A (**1a**) synthesis accomplished, we moved forward to target ficuseptamine B (**1b**). We imagined employing a dual ethenolysis [22] and CM approach for its total synthesis. We envisaged that aryl ketone **9b**, which is a different regioisomer to aryl ketone **9a**, could be achieved by ethenolysis of the Claisen-Schmidt product **17**, using a suitable olefin metathesis catalyst to dissect the internal alkene of **17** to give the desired terminal olefin **9b** (Scheme 4). We also thought that this method would allow access to styrene derivatives (e.g., compounds such as **18**), which are important building blocks in organic chemistry.




**Scheme 4.** Synthetic plan for the synthesis of aryl ketone **9b** via a Claisen-Schmidt reaction followed by ethenolysis.

We began the synthesis towards ficuseptamine B by first preparing the Claisen-Schmidt product **17**. We initially combined 3-hydroxy-4-methoxyacetophenone **15** and 3-hydroxy-4-methoxybenzaldehyde **16** under aqueous NaOH conditions in EtOH, which provided chalcone **17** in 46% yield (entry 1, Table 2). The use of cesium carbonate ( $\text{Cs}_2\text{CO}_3$ ) as the base in EtOH led to **17** in 41% yield (entry 2, Table 2). However, efficient synthesis of **17** was achieved using  $\text{SOCl}_2/\text{EtOH}$  as a catalyst system (acid catalysis) [23] to afford **17** in 83% yield (entry 3, Table 2).

**Table 2.** Synthesis of Claisen-Schmidt product **17** under various catalysis conditions. <sup>a</sup> All reactions were carried out using ketone **15** (1 equiv.), aldehyde **16** (1 equiv.), and catalyst in EtOH at 23 °C. <sup>b</sup> NaOH (10% w/v).


Entry	Catalyst	Equivalent	Time (h)	Yield (%) <sup>a</sup>
1	NaOH <sup>b</sup>	2	16	46
2	$\text{Cs}_2\text{CO}_3$	2	16	41
3	$\text{SOCl}_2$	1	4	83

With the Claisen-Schmidt product **17** in hand, we employed the conditions reported by Diver and co-workers with slight modification for its ethenolysis [24]. Exposing **17** to ethylene gas (60 psi pressure) with Hoveyda-Grubbs II **7** and using 1,2-DCE (1,2-dichloroethane) as a solvent at 40 °C delivered aryl ketone **9b** in 71% yield (Scheme 5).



**Scheme 5.** Ethenolysis of chalcone **17** to deliver aryl ketone **9b**.

To the best of our knowledge, this is the first time ethenolysis has been applied to cleave a chalcone compound (i.e., structure such as **17**). Importantly, no isomerization [25] of the double bond is possible, given the structure of chalcone **17**, which lacks any methylene groups adjacent to the double bond. Having accomplished the synthesis of aryl ketone **9a** through ethenolysis, we employed the one-pot, two-step CM/hydrogenation protocol previously used in ficuseptamine A synthesis. Gratifyingly, subjecting aryl ketone **9b** and terminal olefin **10** to our optimized CM conditions (Hoveyda-Grubbs II **7** (10 mol %), CH<sub>2</sub>Cl<sub>2</sub>, 40 °C) followed by one-pot hydrogenation delivered ficuseptamine B in 69% yield (Scheme 6).



**Scheme 6.** Synthesis of ficuseptamine B (**1b**) by one-pot CM/hydrogenation sequence.

The spectroscopic data of the synthetic ficuseptamines A and B were identical to those reported by Shin-ya and co-workers [1]. The described chemistry for the synthesis of ficuseptamines A and B through CM allows the generation of various analogues of these natural products in a straightforward manner, which could have other biological activities, such as potential ligands for the 5-HT<sub>7</sub> receptor [26].

### 3. Conclusions

In summary, we have reported a highly efficient methodology for the first total synthesis of ficuseptamines A and B through a CM strategy. A sequential one-pot, two-step CM/hydrogenation procedure was employed to expediently accomplish their total synthesis.

### 4. Materials and Methods

#### 4.1. General Chemistry Experimental

Chemical reactions were performed in over-dried glassware under nitrogen and anhydrous conditions, unless otherwise stated. Reactions were magnetically stirred using a Teflon-coated stir bar and monitored by pre-coated silica gel aluminum plates (0.25 mm thickness) with a fluorescent indicator (254 nm), using UV light as the visualizing agent. Alternatively, oxidative staining using an aqueous basic solution of KMnO<sub>4</sub> and heat was carried out for visualization. Silica gel (60 Å, 200–425 mesh) was used for flash column chromatography. Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker 400 MHz spectrometer (Bruker, Billerica, MA, USA) in acetone-*d*<sub>6</sub>, CDCl<sub>3</sub>, or DMSO-*d*<sub>6</sub> as the solvent. Chemical shifts are reported in parts per million (ppm) with reference to the hydrogenated residues of the deuterated solvent as the internal standard. Coupling constants (*J* values) are recorded in Hertz (Hz), and signal patterns are expressed as follows: singlet (s), doublet (d), dd (doublet of doublets), triplet (t), quintet (quint), and multiplet (m). Elemental analyses were performed on a 2400 Perkin Elmer Series II analyzer (PerkinElmer, Inc., Waltham, MA, USA).

High-resolution mass spectrometry was conducted using a Micromass Q-ToF mass spectrometer (Waters Corporation, Milford, MA, USA).

#### 4.2. Experimental Procedures for Chemical Synthesis and Characterization Data of Compounds

##### 4.2.1. Synthesis of 1-(4-Hydroxy-3-methoxyphenyl)prop-2-en-1-one (9a)

A round-bottom flask equipped with a magnetic stir bar was charged with 3-hydroxy-1-(4-hydroxy-3-methoxyphenyl)propan-1-one **11** (2.52 g, 12.8 mmol) and conc. HBr (30 mL) was then added. The reaction mixture was then stirred at 95 °C for 2 h. The reaction mixture was cooled to room temperature and the resulting precipitate was filtered, washed with ice-cold H<sub>2</sub>O, and dried to afford 3-bromo-1-(4-hydroxy-3-methoxyphenyl)propan-1-one **12** (quantitative yield, 3.09 g, 93%) as a white solid, which was judged to be of good purity by TLC analysis and mass spectrometry, and carried forward in crude form to the next step. To a stirred solution of 3-bromo-1-(4-hydroxy-3-methoxyphenyl)propan-1-one **12** (3 g, 11.6 mmol) in dry benzene (50 mL), was added, dropwise, a solution of DBU (2.08 mL, 13.9 mmol) in dry benzene (5 mL). A condenser was attached, and the reaction mixture was stirred at 70 °C for 3 h. The solvent was removed in vacuo, and the crude product was extracted with EtOAc (three times). The combined organic layers were washed with H<sub>2</sub>O, brine, dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The crude product was then purified by silica gel column chromatography to afford **9a** (1.42 g, 69%) as a white solid. <sup>1</sup>H-NMR (400 MHz, acetone-*d*<sub>6</sub>): δ 7.66 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.61 (d, *J* = 2.0 Hz, 1H), 7.40 (dd, *J* = 17.0, 10.4 Hz, 1H), 6.95 (d, *J* = 8.4 Hz, 1H), 6.36 (dd, *J* = 17.0, 2.0 Hz, 1H), 5.86 (dd, *J* = 10.4, 2.0 Hz, 1H), 3.93 (s, 3H); HRMS calcd. for C<sub>10</sub>H<sub>11</sub>O<sub>3</sub> [M + H]<sup>+</sup> 179.0708, found 179.0713. Anal. calcd. for C<sub>10</sub>H<sub>10</sub>O<sub>3</sub>: C, 67.41; H, 5.66. Found: C, 67.31; H, 5.55.

##### 4.2.2. Synthesis of Ficuseptamine A by a One-Pot Cross Metathesis/Hydrogenation Procedure (1a)

To a stirred solution of aryl ketone **9a** (315 mg, 1.77 mmol) and *N,N*-dimethyl-4-pentene-1-amine **10** (100 mg, 0.885 mmol) in dry and degassed CH<sub>2</sub>Cl<sub>2</sub> (5 mL), was added Hoveyda-Grubbs second generation catalyst **7** (55 mg, 0.0885 mmol, 10 mol %). The reaction mixture was then deoxygenated by performing vacuum/N<sub>2</sub> cycles four times and stirred at 40 °C for 10 h. After the completion of the reaction, Pd/C (10 wt %) was added, and the N<sub>2</sub> atmosphere was substituted with H<sub>2</sub> by performing vacuum/H<sub>2</sub> cycles four times. The reaction mixture was then stirred under a double layer H<sub>2</sub> balloon at 23 °C for 16 h. The Pd/C catalyst was removed by filtration through a pad of Celite<sup>®</sup>, followed by washing of the filter cake with CH<sub>2</sub>Cl<sub>2</sub> (10 mL), and the filtrate was evaporated in vacuo. The crude product was purified directly by silica gel column chromatography to afford ficuseptamine A (**1a**) as a white solid (153 mg, 65%). Spectroscopic data for synthetic ficuseptamine A matched literature data of natural ficuseptamine A [1]. <sup>1</sup>H-NMR (400 MHz, acetone-*d*<sub>6</sub>): δ 7.57 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.54 (d, *J* = 2.0 Hz, 1H), 6.89 (d, *J* = 8.4 Hz, 1H), 3.89 (s, 3H), 2.93 (t, *J* = 7.2 Hz, 2H), 2.21 (t, *J* = 7.2 Hz, 2H), 2.13 (s, 2 × 3H), 1.68 (quint, *J* = 7.2 Hz, 2H), 1.47 (quint, *J* = 7.2 Hz, 2H), 1.37 (quint, *J* = 7.2 Hz, 2H); <sup>13</sup>C-NMR (100 MHz, acetone-*d*<sub>6</sub>) δ: 198.6, 152.1, 148.3, 130.6, 123.8, 115.3, 111.5, 60.2, 56.2, 45.6, 38.4, 28.3, 27.8, 25.3; HRMS calcd. for C<sub>15</sub>H<sub>24</sub>NO<sub>3</sub> [M + H]<sup>+</sup> 266.1756, found 266.1767. Anal. calcd. for C<sub>15</sub>H<sub>23</sub>NO<sub>3</sub>: C, 67.90; H, 8.74; N, 5.18. Found: C, 67.76; H, 8.70; N, 5.07.

##### 4.2.3. Synthesis of (2E)-1,3-Bis(3-Hydroxy-4-methoxyphenyl)prop-2-en-1-one (17)

Compound **17** was synthesized using a previously reported method, except that it required purification [23]. To a stirred solution of 3-hydroxy-4-methoxyacetophenone **15** (1.20 g, 7.89 mmol) and 3-hydroxy-4-methoxybenzaldehyde **16** (1.31 g, 7.89 mmol) in absolute EtOH (5 mL), was added thionyl chloride (0.58 mL, 7.89 mmol) dropwise and the reaction mixture was stirred at 23 °C for 4 h. The reaction mixture was precipitated by the addition of H<sub>2</sub>O (~5 mL), and the resulting precipitate was filtered, washed with ice-cold H<sub>2</sub>O, and ice-cold EtOH. After the crude product was allowed to air dry, purification by recrystallization from EtOH afforded **17** (1.97 g, 83%) as a yellow solid. Analytical

data were in accordance with literature data [27].  $^1\text{H-NMR}$  (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.72 (d,  $J = 16.2$  Hz, 1H), 7.63–7.60 (m, 2H), 7.40 (d,  $J = 16.2$  Hz, 1H), 7.28–7.27 (m, 1H), 7.12 (dd,  $J = 10.4, 2.0$  Hz, 1H), 6.93 (d,  $J = 8.2$  Hz, 1H), 6.85 (d,  $J = 8.2$  Hz, 1H), 3.98 (s, 3H), 3.94 (s, 3H);  $^{13}\text{C NMR}$  (100 MHz,  $\text{DMSO-}d_6$ ):  $\delta$  188.5, 152.7, 150.7, 147.0, 146.9, 144.3, 131.3, 128.1, 122.8, 122.4, 119.8, 115.2, 114.8, 112.5, 111.8, 56.3, 56.2; HRMS calcd. for  $\text{C}_{17}\text{H}_{17}\text{O}_5$   $[\text{M} + \text{H}]^+$  301.1076, found 301.1065. Anal. calcd. for  $\text{C}_{17}\text{H}_{16}\text{O}_5$ : C, 67.99; H, 5.37. Found: C, 67.80; H, 5.41.

#### 4.2.4. Synthesis of 1-(3-Hydroxy-4-methoxyphenyl)prop-2-en-1-one (9b)

Compound **9b** was synthesized using the slightly modified reaction conditions of Diver et al. [24]. To an inert and oven-dried high-pressure flask, was added compound **17** (800 mg, 2.67 mmol), dry and degassed 1,2-dichloroethane (35 mL), and Hoveyda-Grubbs second generation catalyst **7** (42 mg, 0.067 mmol). The flask was purged with ethylene for 5 min, pressurized to 60 psi, and stirred at 40 °C for 12 h, after which time TLC analysis indicated consumption of the internal alkene **17**. The pressure was then slowly vented, and the solvent was evaporated in vacuo. The crude product was then purified directly by silica gel column chromatography, to afford **9b** (337 mg, 71%) as a white solid.  $^1\text{H-NMR}$  (400 MHz, acetone- $d_6$ ):  $\delta$  7.59 (dd,  $J = 8.4, 2.0$  Hz, 1H), 7.50 (d,  $J = 2.0$  Hz, 1H), 7.33 (dd,  $J = 17.0, 10.4$  Hz, 1H), 7.07 (d,  $J = 8.4$  Hz, 1H), 6.33 (dd,  $J = 17.0, 2.0$  Hz, 1H), 5.84 (dd,  $J = 10.4, 2.0$  Hz, 1H), 3.94 (s, 3H);  $^{13}\text{C NMR}$  (100 MHz, acetone- $d_6$ ):  $\delta$  188.9, 153.0, 147.7, 133.2, 131.8, 128.9, 122.8, 115.7, 111.8, 56.5; HRMS calcd. for  $\text{C}_{10}\text{H}_{11}\text{O}_3$   $[\text{M} + \text{H}]^+$  179.0708, found 179.0719. Anal. calcd. for  $\text{C}_{10}\text{H}_{10}\text{O}_3$ : C, 67.41; H, 5.66. Found: C, 67.35; H, 5.59.

#### 4.2.5. Synthesis of Ficuseptamine B by a One-Pot Cross Metathesis/Hydrogenation Procedure (1b)

The experimental procedure for the synthesis of ficuseptamine A (**1a**) was followed, except that aryl ketone **9b** was used as the cross metathesis partner with *N,N*-dimethyl-4-pentene-1-amine **10** to afford ficuseptamine B (**1b**) (162 mg, 69%) as a white solid. Spectroscopic data for synthetic ficuseptamine B matched literature data of natural ficuseptamine B [1].  $^1\text{H-NMR}$  (400 MHz, acetone- $d_6$ ):  $\delta$  7.52 (dd,  $J = 8.5, 2.0$  Hz, 1H), 7.46 (d,  $J = 2.0$  Hz, 1H), 7.01 (d,  $J = 8.5$  Hz, 1H), 3.90 (s, 3H), 2.90 (t,  $J = 7.2$  Hz, 2H), 2.24 (t,  $J = 7.2$  Hz, 2H), 2.15 (s, 2  $\times$  3H), 1.66 (quint,  $J = 7.2$  Hz, 2H), 1.48 (quint,  $J = 7.2$  Hz, 2H), 1.37 (quint,  $J = 7.2$  Hz, 2H);  $^{13}\text{C-NMR}$  (100 MHz, acetone- $d_6$ ):  $\delta$  198.9, 152.4, 147.3, 131.7, 121.7, 115.2, 111.5, 60.1, 56.3, 45.5, 38.5, 28.1, 27.7, 25.2; HRMS calcd. for  $\text{C}_{15}\text{H}_{24}\text{NO}_3$   $[\text{M} + \text{H}]^+$  266.1756, found 266.1741. Anal. calcd. for  $\text{C}_{15}\text{H}_{23}\text{NO}_3$ : C, 67.90; H, 8.74; N, 5.28. Found: C, 67.78; H, 8.66; N, 5.19.

**Author Contributions:** Conceived of and designed the experiments: H.M.A.H. Performed the experiments: H.M.A.H. Analyzed the data: H.M.A.H. Wrote the paper: H.M.A.H.

**Acknowledgments:** This work was funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, under grant number G-1436-141-202. The author, therefore, would like to thank DSR for financial support.

**Conflicts of Interest:** The author declares no conflict of interest.

## References

1. Ueda, J.-Y.; Takagi, M.; Shin-ya, K. Aminocaprophenone- and pyrrolidine-type alkaloids from the leaves of *Ficus septica*. *J. Nat. Prod.* **2009**, *72*, 2181–2183. [[CrossRef](#)] [[PubMed](#)]
2. Battaglia, U.; Moody, C.J. A short synthesis of the triazolopyrimidine antibiotic essramycin. *J. Nat. Prod.* **2010**, *73*, 1938–1939. [[CrossRef](#)] [[PubMed](#)]
3. Wang, W.; Zeng, Y.H.; Osman, K.; Shinde, K.; Rahman, M.; Gibbons, S.; Mu, Q. Norlignans, acylphloroglucinols, and a dimeric xanthone from *Hypericum chinense*. *J. Nat. Prod.* **2010**, *73*, 1815–1820. [[CrossRef](#)] [[PubMed](#)]
4. Pais, G.C.G.; Zhang, X.; Marchand, C.; Neamati, N.; Cowansage, K.; Svarovskaia, E.S.; Pathak, V.K.; Tang, Y.; Nicklaus, M.; Pommier, Y.; et al. Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors. *J. Med. Chem.* **2002**, *45*, 3184–3194. [[CrossRef](#)] [[PubMed](#)]
5. Purser, S.; Moore, P.R.; Swallow, S.; Gouverneur, V. Fluorine in medicinal chemistry. *Chem. Soc. Rev.* **2008**, *37*, 320–330. [[CrossRef](#)] [[PubMed](#)]



6. Han, C.; Salyer, A.E.; Kim, E.H.; Jiang, X.; Jarrad, R.E.; Powers, M.S.; Kirchoff, A.M.; Salvador, T.K.; Chester, J.A.; Hockerman, G.H.; et al. Evaluation of difluoromethyl ketones as agonists of the  $\gamma$ -aminobutyric acid type B (GABA<sub>B</sub>) receptor. *J. Med. Chem.* **2013**, *56*, 2456–2465. [[CrossRef](#)] [[PubMed](#)]
7. Vougioukalakis, G.C.; Grubbs, R.H. Ruthenium-based heterocyclic carbene-coordinated olefin metathesis catalysts. *Chem. Rev.* **2010**, *110*, 1746–1787. [[CrossRef](#)] [[PubMed](#)]
8. Hassan, H.M.A. Recent applications of ring-closing metathesis in the synthesis of lactams and macrolactams. *Chem. Commun.* **2010**, *46*, 9100–9106. [[CrossRef](#)] [[PubMed](#)]
9. Connon, S.J.; Blechert, S. Recent developments in olefin cross-metathesis. *Angew. Chem. Int. Ed.* **2003**, *42*, 1900–1923. [[CrossRef](#)] [[PubMed](#)]
10. Hoveyda, A.H.; Zhugralin, A.R. The remarkable metal-catalysed olefin metathesis reaction. *Nature* **2007**, *450*, 243–251. [[CrossRef](#)] [[PubMed](#)]
11. Nicolaou, K.C.; Bulger, P.G.; Sarlah, D. Metathesis reactions in total synthesis. *Angew. Chem. Int. Ed.* **2005**, *44*, 4490–4527. [[CrossRef](#)] [[PubMed](#)]
12. Fürstner, A. Metathesis in total synthesis. *Chem. Commun.* **2011**, *47*, 6505–6511. [[CrossRef](#)] [[PubMed](#)]
13. Chatare, V.K.; Andrade, R.B. Total synthesis of (–)-albocycline. *Angew. Chem. Int. Ed.* **2017**, *56*, 5909–5911. [[CrossRef](#)] [[PubMed](#)]
14. Herbert, M.B.; Marx, V.M.; Pederson, R.L.; Grubbs, R.H. Concise syntheses of insect pheromones using Z-selective cross metathesis. *Angew. Chem. Int. Ed.* **2013**, *52*, 310–314. [[CrossRef](#)] [[PubMed](#)]
15. Mann, T.J.; Speed, A.W.H.; Schrock, R.R.; Amir, H.; Hoveyda, A.H. Catalytic Z-selective cross-metathesis with secondary silyl- and benzyl-protected allylic ethers: Mechanistic aspects and applications to natural product synthesis. *Angew. Chem. Int. Ed.* **2013**, *52*, 8395–8400. [[CrossRef](#)] [[PubMed](#)]
16. Herbert, M.B.; Grubbs, R.H. Z-selective cross metathesis with ruthenium catalysts: Synthetic applications and mechanistic implications. *Angew. Chem. Int. Ed.* **2015**, *54*, 5018–5024. [[CrossRef](#)] [[PubMed](#)]
17. Hassan, H.M.A.; Brown, F.K. A convenient approach to acyclic unsaturated amino acids via ring-closing metathesis. *Chem. Commun.* **2010**, *46*, 3013–3015. [[CrossRef](#)] [[PubMed](#)]
18. Hong, S.H.; Wenzel, A.G.; Salguero, T.T.; Day, M.W.; Grubbs, R.H. Decomposition of ruthenium olefin metathesis catalysts. *J. Am. Chem. Soc.* **2007**, *129*, 7961–7968. [[CrossRef](#)] [[PubMed](#)]
19. Chatterjee, A.K.; Choi, T.-L.; Sanders, D.P.; Grubbs, R.H. A general model for selectivity in olefin cross metathesis. *J. Am. Chem. Soc.* **2003**, *125*, 11360–11370. [[CrossRef](#)] [[PubMed](#)]
20. Boulard, L.; BouzBouz, S.; Cossy, J.; Franck, X.; Figadère, B. Two successive one-pot reactions leading to the expeditious synthesis of (–)-centrolobine. *Tetrahedron Lett.* **2004**, *45*, 6603–6605. [[CrossRef](#)]
21. Hayashi, Y. Pot economy and one-pot synthesis. *Chem. Sci.* **2016**, *7*, 866–880. [[CrossRef](#)] [[PubMed](#)]
22. Bidange, J.; Fischmeister, C.; Bruneau, C. Ethenolysis: A green catalytic tool to cleave carbon—Carbon double bonds. *Chem. Eur. J.* **2016**, *22*, 12226–12244. [[CrossRef](#)] [[PubMed](#)]
23. Petrov, O.; Ivanova, Y.; Gerova, M. SOCl<sub>2</sub>/EtOH: Catalytic system for synthesis of chalcones. *Catal. Commun.* **2008**, *9*, 315–316. [[CrossRef](#)]
24. Clark, J.R.; French, J.M.; Diver, S.T. Alkene metathesis approach to  $\beta$ -unsubstituted anti-allylic alcohols and their use in ene-yne metathesis. *J. Org. Chem.* **2012**, *77*, 1599–1604. [[CrossRef](#)] [[PubMed](#)]
25. Hong, S.H.; Sanders, D.P.; Lee, C.W.; Grubbs, R.H. Prevention of undesirable isomerization during olefin metathesis. *J. Am. Chem. Soc.* **2005**, *127*, 17160–17161. [[CrossRef](#)] [[PubMed](#)]
26. Perrone, R.; Berardi, F.; Colabufo, N.A.; Lacivita, E.; Leopoldo, M.; Tortorella, V. Synthesis and structure-affinity relationships of 1-[ $\omega$ -(4-aryl-1-piperazinyl) alkyl]-1-aryl ketones as 5-HT<sub>7</sub> receptor ligands. *J. Med. Chem.* **2003**, *46*, 646–649. [[CrossRef](#)] [[PubMed](#)]
27. Leow, P.-C.; Bahety, P.; Boon, C.P.; Lee, C.Y.; Tan, K.L.; Yang, T.; Ee, P.-L.R. Functionalized curcumin analogs as potent modulators of the Wnt/ $\beta$ -catenin signaling pathway. *Eur. J. Med. Chem.* **2014**, *71*, 67–80. [[CrossRef](#)] [[PubMed](#)]

**Sample Availability:** Samples of the compounds are not available from the author.



© 2018 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).